Skip to main content

Table 6 The most frequent (≥2)a QT-DDIs along with their levels and TdP risks of drugs involved in these QT-DDIs stratified with respect to various types of cancer

From: Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study

QT-DDIs TdP risk Levels of QT-DDIs Frequency
Drug 1 Drug 2 Severity Documentation QT-DDIs: n (%)b
Breast cancer
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 31 (10.8)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 31 (10.8)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 31 (10.8)
Gastrointestinal cancer
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 26 (9)
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 13 (4.5)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 12 (4.2)
 Dolasetron-Ondansetron Possible risk of TdP Known risk of TdP Major Fair 2 (0.7)
Gynecologic cancer
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 8 (2.8)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 6 (2.1)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 6 (2.1)
Genitourinary cancer
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 7 (2.4)
Musculoskeletal cancer
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 4 (1.4)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 4 (1.4)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 4 (1.4)
Chronic lymphocytic leukemia
 Dolasetron-Metronidazole Possible risk of TdP Conditional risk of TdP Major Fair 3 (1)
 Ciprofloxacin-Dolasetron Known risk of TdP Possible risk of TdP Major Fair 2 (0.7)
 Metronidazole-Nilotinib Conditional risk of TdP Conditional risk of TdP Major Fair 2 (0.7)
Non hodgkin lymphoma
 Ciprofloxacin-Metronidazole Known risk of TdP Conditional risk of TdP Major Fair 2 (0.7)
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 2 (0.7)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
Adenocarcinoma
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 2 (0.7)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
Head and neck cancer
 Ciprofloxacin-Ondansetron Known risk of TdP Known risk of TdP Major Fair 2 (0.7)
 Ciprofloxacin-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
Neurological cancer
 Ondansetron-Prochlorperazine Known risk of TdP Not included in lists Major Fair 2 (0.7)
Chronic myelogenous leukemia
 Metronidazole-Nilotinib Conditional risk of TdP Conditional risk of TdP Major Fair 2 (0.7)
  1. AZCERT Arizona Center for Education and Research on Therapeutics, TdP torsades de pointes, QT DDIs QT prolonging drug-drug interactions
  2. aAll results have been mentioned in Additional file 2: Table S2
  3. bPercentage calculated in total number of QT-DDIs i.e., 288